生长抑素受体在复发、转移性乳腺癌癌组织中的表达及临床意义(附86例报告)

Expression and clinical significance of SSTR in recurrent metastatit breast cancer:Report of 86 cases

目的:探讨生长抑素受体在复发、转移性乳腺癌癌组织中的表达情况及其临床意义。方法:对近5年来86例复发、转移乳腺癌切除转移病灶、转移灶旁组织和正常组织,进行生长抑素受体测定,将上述三组表达情况进行比较;同时与该86例患者第一次术后的生长抑素受体表达情况进行比较。结果:复发转移癌组织、癌旁组织及正常组织生长抑素受体表达率分别为25.58%-51.16%、2.33%-4.65%和0%;86例复发转移的癌组织与首次发病时的生长抑素受体表达率分别为38.37%和70.93%;P<0.05,有显著差异。结论:乳腺癌复发转移后癌组织中的生长抑素受体表达率明显低于首次发病时的表达率,此类患者病期晚、预后差,对于这类患者在应用生长抑素治疗前应力争获取癌组织,以便选择有效的辅助治疗方法。

Objective：To study the expression of somatostatin receptor（SSTR） in recurrent metastatic breast cancer.Methods： The expression of SSTR was detected in 86 cases of recurrent metastatic cancer,ajacent tissue and normal tissue,and compared with each other and primary breast cancer.Results： The expression of SSTR in recurrent metastatic cancer,ajacent tissure and normal tissue were 25.58%-51.16%,2.33%-4.65% and 0%.The expression of SSTR in 86 cases of recurrent metastatic cancer and primary breast cancer were 38.37% and 70.93%（P0.05）.The difference was statistically significant.Conclusion： The differentiated grade of breast cancer were worse and the expression of SSTR were lower.The therapeutic efficiency were bad for somatostatin in these patients,and it was necessary to obtain the recurrent metastatic breast cancer tissue to detect SSTR before treatment.